NASDAQ:LABP Landos Biopharma (LABP) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free LABP Stock Alerts $22.35 +0.17 (+0.77%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$22.21▼$22.8450-Day Range$5.51▼$22.3652-Week Range$2.50▼$22.84Volume3,928 shsAverage Volume21,593 shsMarket Capitalization$69.73 millionP/E RatioN/ADividend YieldN/APrice Target$20.42 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Landos Biopharma alerts: Email Address Landos Biopharma MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside8.6% Downside$20.42 Price TargetShort InterestHealthy0.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.19) to ($1.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.67 out of 5 starsMedical Sector886th out of 908 stocksPharmaceutical Preparations Industry413th out of 422 stocks 1.0 Analyst's Opinion Consensus RatingLandos Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLandos Biopharma has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.03% of the float of Landos Biopharma has been sold short.Short Interest Ratio / Days to CoverLandos Biopharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Landos Biopharma has recently decreased by 83.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLandos Biopharma does not currently pay a dividend.Dividend GrowthLandos Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LABP. Previous Next 2.8 News and Social Media Coverage News SentimentLandos Biopharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Landos Biopharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for LABP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Landos Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Landos Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of Landos Biopharma is held by insiders.Percentage Held by Institutions49.06% of the stock of Landos Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Landos Biopharma are expected to grow in the coming year, from ($2.19) to ($1.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Landos Biopharma is -6.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Landos Biopharma is -6.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLandos Biopharma has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Landos Biopharma Stock (NASDAQ:LABP)Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.Read More LABP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LABP Stock News HeadlinesApril 17, 2024 | msn.comLandos Biopharma (LABP) Price Target Increased by 154.20% to 12.96April 16, 2024 | prnewswire.comStockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVieApril 26, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.March 27, 2024 | businesswire.comLANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPMarch 27, 2024 | finanznachrichten.deLandos Biopharma, Inc.: AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 27, 2024 | markets.businessinsider.comLeerink Partners Remains a Hold on Landos Biopharma (LABP)March 26, 2024 | prnewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABPMarch 26, 2024 | markets.businessinsider.comAbbVie To Acquire Landos Biopharma At $20.42/share In CashApril 26, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.March 26, 2024 | bizjournals.comAbbVie to buy Landos Biopharma for $137 millionMarch 26, 2024 | finance.yahoo.comWhy Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?March 25, 2024 | investorplace.comWhy Is Landos Biopharma (LABP) Stock Up 168% Today?March 25, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVieMarch 25, 2024 | businesswire.comLABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to ShareholdersMarch 25, 2024 | reuters.comAbbVie to buy Landos to expand pipeline of immunity-related illnessesMarch 25, 2024 | prnewswire.comAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 25, 2024 | globenewswire.comAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 21, 2024 | investorplace.comLABP Stock Earnings: Landos Biopharma Misses EPS for Q4 2023March 21, 2024 | finanznachrichten.deLandos Biopharma, Inc.: Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 ResultsMarch 21, 2024 | benzinga.comRecap: Landos Biopharma Q4 EarningsMarch 21, 2024 | globenewswire.comLandos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 ResultsMarch 6, 2024 | benzinga.comXontogeny, LLC's Net WorthMarch 5, 2024 | finance.yahoo.comWill Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?January 10, 2024 | benzinga.comAmbrx Biopharma Stock (NASDAQ:AMAM) Dividends: History, Yield and DatesJanuary 8, 2024 | finance.yahoo.comLandos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis OrganisationNovember 22, 2023 | msn.comLandos’s NX-13 shows symptom relief in Phase Ib ulcerative colitis trialNovember 21, 2023 | finanznachrichten.deLandos Biopharma, Inc.: Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and ColitisSee More Headlines Receive LABP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Landos Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/26/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LABP CUSIPN/A CIK1785345 Weblandosbiopharma.com Phone540-218-2232FaxN/AEmployees19Year FoundedN/APrice Target and Rating Average Stock Price Target$20.42 High Stock Price Target$20.42 Low Stock Price Target$20.42 Potential Upside/Downside-8.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.92% Return on Assets-49.09% Debt Debt-to-Equity RatioN/A Current Ratio6.09 Quick Ratio6.09 Sales & Book Value Annual Sales$18 million Price / Sales3.87 Cash FlowN/A Price / Cash FlowN/A Book Value$10.20 per share Price / Book2.19Miscellaneous Outstanding Shares3,120,000Free Float3,078,000Market Cap$69.73 million OptionableNot Optionable Beta0.14 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Jennifer Creel (Age 53)Interim Chief Financial Officer Ms. Rebecca Mosig Ph.D.Vice President of Corporate DevelopmentDr. Josep Bassaganya-Riera DVM (Age 49)Ph.D., Advisor Comp: $1.79MKey CompetitorsAnebulo PharmaceuticalsNASDAQ:ANEBJourney MedicalNASDAQ:DERMCarisma TherapeuticsNASDAQ:CARMViveon Health AcquisitionNYSE:VHAQRallybioNASDAQ:RLYBView All CompetitorsInstitutional OwnershipDeltec Asset Management LLCBought 50,000 shares on 4/17/2024Ownership: 1.603%View All Institutional Transactions LABP Stock Analysis - Frequently Asked Questions Should I buy or sell Landos Biopharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Landos Biopharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" LABP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LABP, but not buy additional shares or sell existing shares. View LABP analyst ratings or view top-rated stocks. What is Landos Biopharma's stock price target for 2024? 1 brokers have issued twelve-month price objectives for Landos Biopharma's shares. Their LABP share price targets range from $20.42 to $20.42. On average, they expect the company's stock price to reach $20.42 in the next twelve months. This suggests that the stock has a possible downside of 8.6%. View analysts price targets for LABP or view top-rated stocks among Wall Street analysts. How have LABP shares performed in 2024? Landos Biopharma's stock was trading at $3.66 at the start of the year. Since then, LABP stock has increased by 510.7% and is now trading at $22.35. View the best growth stocks for 2024 here. Are investors shorting Landos Biopharma? Landos Biopharma saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 800 shares, a decline of 83.7% from the March 31st total of 4,900 shares. Based on an average daily volume of 25,200 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company's shares are sold short. View Landos Biopharma's Short Interest. When is Landos Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our LABP earnings forecast. How were Landos Biopharma's earnings last quarter? Landos Biopharma, Inc. (NASDAQ:LABP) issued its earnings results on Thursday, March, 21st. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.91) by $0.08. When did Landos Biopharma's stock split? Landos Biopharma's stock reverse split on the morning of Friday, May 26th 2023. The 1-10 reverse split was announced on Friday, May 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Landos Biopharma IPO? Landos Biopharma (LABP) raised $101 million in an initial public offering on Thursday, February 4th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Raymond James was co-manager. Who are Landos Biopharma's major shareholders? Landos Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Deltec Asset Management LLC (1.60%). Insiders that own company stock include Josep Bassaganya-Riera and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Landos Biopharma? Shares of LABP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LABP) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Landos Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
